A case of myocarditis after COVID-19 vaccination: incidental or consequential?

Alizadeh, Leona S.; Koch, Vitali; Yel, Ibrahim; Gruenewald, Leon D.; Mathies, Daniel; Martin, Simon S.; Vogl, Thomas J.; Rauschning, Dominic; Booz, Christian

doi:10.1016/j.heliyon.2022.e09537

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, noticed that the concentration of Myoglobin for the vaccinated groups was substantially higher (P < 0.0001) in individuals infected with CoV-19 virus, vaccinated more than vaccinated, noninfected with covid-19 and patients that vaccinated, recovery from covid-19 as shown in Figure 4. This result agreed with [47,48] who found an elevated concentration of myoglobin for carditis after administration of the COV-19 mRNA vaccine. Moreover, this risk elevated was more probably to occur following the second vaccination dose compared to the first.…”

Section: Estimation Of Serum Myoglobin Concentrationssupporting

confidence: 91%

Evaluation of some cardiac markers in relation to COVID-19 mRNA vaccine

Al-Azzawi¹,

AL-Eqabi²

2022

JBB

View full text Add to dashboard Cite

Background: Acute myocardial infarction (AMI) is a dangerous cardiovascular illness that has a significant impact on people's health. Several biomarkers, including Myoglobin and troponin I (cTnI) were utilized to diagnose AMI in recent decades. The Troponin I (cTnI) was designated as the "gold standard" cardiac biomarker for the prediction of cardiomyopathy. It's a heart muscle regulating protein found on normal myocyte actin filaments. When cardiac muscles are injured, cTnI, one of the main subunits of the cardiac troponin complex, is released into the circulation (e.g., myocardial infarction). Myoglobin denoted by (symbols Mb and MB) seems to be an iron-and o2-binding protein present in the vertebrate heart and skeletal muscle tissues and, more specifically, nearly all mammals. In humans, MB is only present in the bloodstream following muscle damage. Its primary function is to supply myocytes with oxygen. Also essential to nitric oxide hemostasis was myoglobin. Additionally, it facilitates the detoxification of response oxygen molecules from the body. MB is accountable for most vertebrate muscles' red hue.The aim: To assess the difference in the level of (MYOGLOBIN and TROPONIN_I) between patients with and without mRNA Vaccination. Methods: This study included 125 patients (65 male and 60 female) with vaccinated and non-vaccinated covid-19 with an age range of 20-69 years. These patients are divided into two main groups: 1. vaccinated (vaccinated with COVID-19 infection, vaccinated without COVID-19 disease, vaccinated recovered from the CoV-19 virus),2. unvaccinated (infected with the CoV-19 virus and non-vaccinated, recovered from covid-19 and unvaccinated). The outcome is measured using the Enzyme-linked immunosorbent assay (ELISA) technique. This study was conducted during the period from November 2021 to May 2022 at the Martyr Dr.

show abstract

Section: Estimation Of Serum Myoglobin Concentrationssupporting

confidence: 91%

Evaluation of some cardiac markers in relation to COVID-19 mRNA vaccine

Al-Azzawi¹,

AL-Eqabi²

2022

JBB

View full text Add to dashboard Cite

show abstract

“…Following a more detailed evaluation, 381 articles were included for systematic review. Of these, 134 articles (259 cases) reported cardiovascular complications [ 2 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ,…”

Section: Resultsmentioning

confidence: 99%

Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series

Lee,

Yap,

Amin-Nordin

et al. 2024

Vaccines

View full text Add to dashboard Cite

Following mass vaccinations for the control of the COVID-19 epidemic, a spectrum of cardiac and neurological disorders was reported among vaccinated individuals. This study examined the range of complications documented and factors related to their occurrence. Three electronic databases were searched for case reports and case series with descriptions of cardiac and/or neurological complications in COVID-19 vaccine recipients. A total of 698 vaccinees were included in this review, of which 259 (37.1%) had cardiac and 439 (62.9%) had neurological complications. Inflammatory conditions were the commonest among the cardiac complications; while polyneuropathy, demyelinating diseases and cerebrovascular disorders were the more common neurological complications. The mean age of those with cardiac complications (33.8 years) was much younger than those with neurological complications (49.7 years). There was no notable difference in the gender distribution between these two groups of vaccine recipients. mRNA vaccines (all brands) were associated with almost 90.0% of the cardiac complications, whereas viral vector vaccines were associated with slightly over half (52.6%) of the neurological complications. With regard to the dose, cardiac complications were more common after the second (69.1%), whereas neurological complications were more common after the first dose (63.6%). The majority of the cases had an uncomplicated clinical course. Nevertheless, 5.9% of cases with neurological complications and 2.5% of those with cardiac complications were fatal, underscoring the significance of the consistent surveillance and vigilant monitoring of vaccinated individuals to mitigate these occurrences.

show abstract

Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases

Saputra¹,

Kurniawan²,

Trilistyoati³

et al. 2023

Biomol Biomed

View full text Add to dashboard Cite

Vaccination is significant to control, mitigate, and recover from the destructive effects of coronavirus disease 2019 (COVID-19). The incidence of myocarditis following COVID-19 vaccination has been increasing and growing public concern; however, little is known about it. This study aimed to systematically review myocarditis following COVID-19 vaccination. We included studies containing individual patient data of myocarditis following COVID-19 vaccination published between January 1, 2020 and September 7, 2022 and excluded review articles. Joanna Briggs Institute critical appraisals were used for risk of bias assessment. Descriptive and analytic statistics were performed. A total of 121 reports and 43 case series from five databases were included. We identified 396 published cases of myocarditis and observed that the majority of cases was male patients, happened following the second dose of mRNA vaccine administration, and experienced chest pain as a symptom. Previous COVID-19 infection was significantly associated (p < 0.01; OR, 5.74; 95% CI, 2.42–13.64) with the risk of myocarditis following the administration of the first dose, indicating that its primary mechanism is immune-mediated. Moreover, 63 histopathology examinations were dominated by non-infective subtypes. Electrocardiography and cardiac marker combination is a sensitive screening modality. However, cardiac magnetic resonance is a significant noninvasive examination to confirm myocarditis. Endomyocardial biopsy may be considered in confusing and severe cases. Myocarditis following COVID-19 vaccination is relatively benign, with a median length of hospitalization of 5 days, intensive care unit admission of <12%, and mortality of <2%. The majority was treated with nonsteroidal anti-inflammatory drugs, colchicine, and steroids. Surprisingly, deceased cases had characteristics of being female, older age, non-chest pain symptoms, first-dose vaccination, left ventricular ejection fraction of <30%, fulminant myocarditis, and eosinophil infiltrate histopathology.

show abstract

A case of myocarditis after COVID-19 vaccination: incidental or consequential?

Cited by 3 publications

References 10 publications

Evaluation of some cardiac markers in relation to COVID-19 mRNA vaccine

Evaluation of some cardiac markers in relation to COVID-19 mRNA vaccine

Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series

Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases

Contact Info

Product

Resources

About